Home > Research > Publications & Outputs > Introduction

Electronic data

  • Introduction

    Rights statement: This article is (c) Emerald Group Publishing and permission has been granted for this version to appear here. Emerald does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express permission from Emerald Group Publishing Limited.

    Accepted author manuscript, 232 KB, PDF-document

    Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License

Links

Text available via DOI:

View graph of relations

Introduction: cultivation, medication, activism and cannabis policy

Research output: Contribution to journalEditorial

Published
Close
<mark>Journal publication date</mark>4/06/2018
<mark>Journal</mark>Drugs and Alcohol Today
Issue number2
Volume18
Number of pages7
Pages (from-to)73-79
Publication statusPublished
Early online date9/05/18
Original languageEnglish

Abstract

On Friday 23rd February 2018 the medical cannabis bill introduced by UK Member of Parliament Paul Flynn went in for its second reading in the House of Commons. To the disappointment of several hundred activists assembled on the patch of green on Parliament Square in the freezing cold it never got to a vote, as the discussion on the preceding motion, Overseas Electors, dragged on.
The event captured many of the issues transforming the field of drug policy, at least as related to cannabis. A large number of demonstrators were middle aged, a few had rolled up in wheel chairs, and the police were keeping a respectful distance. Cannabis use in the UK, as in many other countries, has come of age, its
respectability confirmed by the rising flow of scientific evidence of its therapeutic
benefits. Politics, however, is out of step with scientific advances and changing social mores, held back by the counter weight of vested interests, the arrogance of political elites, and sheer inertia. Cannabis, whether for medical or non-medical use, remains illegal in the UK3, and most other countries, even as a growing number of jurisdictions change policy.

Bibliographic note

This article is (c) Emerald Group Publishing and permission has been granted for this version to appear here. Emerald does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express permission from Emerald Group Publishing Limited.